Eli Lilly with promising oncology presentations at ESMO

Eli Lilly on Sunday presented data from results of testing its two oncology products; for registration of oral selpercatinib monotherapy, for the treatment of RET-altered thyroid cancers, and its abemaciclib branded Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer

Read more

Lilly soon seeks regulatory approval for RET fusion-positive NSCLC treatment

Eli Lilly’s test of oral selpercatinib monotherapy for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC) saw a 68 percent objective response rate (ORR), and also showed that safety analysis of all 531 patients enrolled to LIBRETTO-001, selpercatinib was well-tolerated, with only 9 patients (1.7%) discontinuing therapy due to treatment-related toxicity.

Read more

Worldwide Chemotherapy Drugs Market Outlook to 2023 – Featuring Pfizer, Eli Lilly, Celgene, Bristol-Myers Squibb, Merck & Co, GlaxoSmithKline, Novartis, Sanofi, and Teva Pharmaceutical Industries – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral,

Read more